Advertisement

Zeitschrift für Rheumatologie

, Volume 73, Issue 3, pp 244–250 | Cite as

Sicherheit der Rheumatherapie im Alter

  • K. KrügerEmail author
  • A. Strangfeld
  • C. Kneitz
Leitthema

Zusammenfassung

Der Anteil an geriatrischen Patienten wird auch im Krankengut des Rheumatologen größer, wofür in erster Linie der demographischen Wandel und die im Zuge besserer Behandlungsmöglichkeiten geringere Mortalität verantwortlich sind. Die medikamentöse Behandlung älterer Rheumapatienten bringt jedoch spezielle Probleme mit sich. So weist diese Altersgruppe pharmakokinetische Besonderheiten auf, außerdem führen häufig vorhandene Multimorbidität und Multimedikation zu vermehrten Interaktionsrisiken und schlechterer Adhärenz. Gleichwohl gelten für diese Patienten die gleichen Therapieprinzipien und -ziele wie für die jüngere Klientel. Hier die richtige Balance zu finden, fordert vom Rheumatologen Fingerspitzengefühl bei der Wahl der in jedem einzelnen Fall bestgeeigneten Medikamente. Keineswegs sollte die Angst vor vermeintlich größeren Risiken dazu führen, dass Patienten dieses Alters nicht adäquat versorgt werden – ein Sachverhalt, der leider durch eine Reihe von Untersuchungen nahegelegt wird.

Schlüsselwörter

Antirheumatika Medikamentöse Therapie Medikamentensicherheit Geriatrische Patienten Medikamentöse Interaktionen 

Safety of antirheumatic drug treatment in the elderly

Abstract

Mainly due to the general demographic changes and decreasing mortality in rheumatic diseases based on therapeutic progress, the proportion of older patients treated by rheumatologists is growing. Drug treatment in the elderly, however, harbors certain risks including age-specific pharmacokinetic features and high rates of multimorbidity and polypharmacy resulting in a risk of drug interactions and adherence problems. Nevertheless, older patients suffering from rheumatic diseases ought to be treated with the same intensity and same targets as the younger counterparts. Bearing all these facts in mind it is a balancing act for rheumatologists to find an optimal treatment for the individual elderly patient. Fear of risks should not lead to hesitant use of drugs leaving these patients alone with treatment deficits, as some studies have suggested.

Keywords

Antirheumatic drugs Drug treatment Drug safety Elderly patients Drug interactions 

Notes

Interessenkonflikt

Die Autoren weisen auf folgende Beziehungen hin: K. Krüger: Vorträge und/oder Beratungstätigkeit für die Firmen Abbvie, Bristol Myers Squibb, Medac, MSD, Pfizer, Roche, UCB. Für A. Strangfeld und C. Kneitz liegt kein Interessenkonflikt vor. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Alivernini S, Mazzotta D, Zoli A, Ferraccioli G (2009) Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis. Drugs Aging 26:395–402PubMedCrossRefGoogle Scholar
  2. 2.
    Bathon JM, Fleischmann RM, Heijde DM van der et al (2006) Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 33:234–243PubMedGoogle Scholar
  3. 3.
    Bernatsky S, Ehrmann-Feldman D (2008) Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis. Drugs Aging 25:879–884PubMedCrossRefGoogle Scholar
  4. 4.
    Chan J, Sanders DC, Du L, Pillans PI (2004) Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 38:1206–1211PubMedCrossRefGoogle Scholar
  5. 5.
    Christensen AM, Thagaard MS, Stentoft J (2013) Wrong administration of methotrexate can lead to fatal haematological complications in elderly patients. Ugeskr Laeger 175:435–436PubMedGoogle Scholar
  6. 6.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRefGoogle Scholar
  7. 7.
    Cottone M, Kohn A, Daperno M et al (2011) Advanced age is an independent risk factor for severe infections and mortality in patients given anti – tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 9:30–35PubMedCrossRefGoogle Scholar
  8. 8.
    Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 48:133–143PubMedCrossRefGoogle Scholar
  9. 9.
    Del Rincon I, Battafarano DF, Restrepo JF et al (2013) Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. doi:10.1002/art.38210Google Scholar
  10. 10.
    Diaz-Borjon A (2009) Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging 26:273–293PubMedCrossRefGoogle Scholar
  11. 11.
    Dixon WG, Watson K, Lunt M et al (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905–2912PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Dixon WG, Abrahamowicz M, Beauchamp ME et al (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case – control analysis. Ann Rheum Dis 71:1128–1133PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Doggrell SA (2010) Adherence to medicines in the older-aged with chronic conditions. Drugs Aging 27:239–254PubMedCrossRefGoogle Scholar
  14. 14.
    Dougados M, Soubrier M, Antunez A et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Drosos AA (2003) Methotrexate intolerance in elderly patients with rheumatoid arthritis. What are the alternatives? Drugs Aging 20:720–736CrossRefGoogle Scholar
  16. 16.
    Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126PubMedCrossRefGoogle Scholar
  17. 17.
    Fiehn C (2006) Der multimorbide ältere Rheumapatient. Z Rheumatol 65:472–481PubMedCrossRefGoogle Scholar
  18. 18.
    Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156PubMedCrossRefGoogle Scholar
  19. 19.
    Harrold L, Reed G, Saunders K et al (2012) Patient and provider factors associated with compliance with rheumatoid arthritis treatment recommendations. Ann Rheum Dis 71(Suppl 3):461Google Scholar
  20. 20.
    Harrold LR, Briesbacher BA, Peterson D et al (2013) Cost-related medication nonadherence in older rheumatoid arthritis patients. J Rheumatol 40:137–143PubMedCrossRefGoogle Scholar
  21. 21.
    Hirshberg B, Muszkat M, Schlesinger O, Rubinow A (2000) Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J 76:787–789PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Hopkins AC, Martinez-Marti M, Reed GW et al (2013) Effectiveness of TNF-a‘ inhibitor therapy does not differ between elderly and younger patients with rheumatoid arthritis: results from the corrona registry. Arthritis Rheum 65(Suppl):S608CrossRefGoogle Scholar
  23. 23.
    Hughes CM (2004) Medication non-adherence in the elderly. Drugs Aging 21:793–811PubMedCrossRefGoogle Scholar
  24. 24.
    Huscher D, Thiele K, Gromnica-Ihle E et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119–1124PubMedCrossRefGoogle Scholar
  25. 25.
    Huscher D, Sengler C, Gromnica-Ihle E et al (2013) Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol 31:256–262PubMedGoogle Scholar
  26. 26.
    Köller MD, Aletaha D, Funovits J et al (2009) Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology 48:1575–1580PubMedCrossRefGoogle Scholar
  27. 27.
    Krüger K (2012) Medikamentöse Interaktionen in der Rheumatologie. Z Rheumatol 71:209–216PubMedCrossRefGoogle Scholar
  28. 28.
    Lakomek HJ, Brabant T, Lakomek M, Lüttje D (2013) Multimorbidität bei älteren Rheumapatienten – Teil 2. Z Rheumatol 72:539–546PubMedCrossRefGoogle Scholar
  29. 29.
    McElnay JC, McCallion CR (1998) Adherence and the elderly. In: Myers LB et al (Hrsg) Adherence to treatment in medical conditions. Harwood Acad. Publ., Amsterdam, S 223–253Google Scholar
  30. 30.
    Ng B, Chu A, Khan MM (2013) A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ Open 3:e002468. doi 10.1136/bmjopen-2012-002468PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Radovits BJ, Kievit W, Laan RFJM (2009) Tumour necrosis factor-a antagonists in the management of rheumatoid arthritis in the elderly. Drugs Aging 26:647–664PubMedCrossRefGoogle Scholar
  32. 32.
    Ranganath VK, Maranian P, Elashoff DA et al (2013) Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology 52:1809–1817PubMedCrossRefGoogle Scholar
  33. 33.
    Saxena A, Balaramnavar VM, Hohlfeld T, Saxena AK (2013) Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. Eur J Pharmacol 721:215–224PubMedCrossRefGoogle Scholar
  34. 34.
    Schiff MH, Yu EB, Weinblatt ME et al (2006) Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 23:167–178PubMedCrossRefGoogle Scholar
  35. 35.
    Spagnoli A, Ostino G, Borga AD et al (1989) Drug compliance and unreported drugs in the elderly. J Am Geriatr Soc 37:619–624PubMedGoogle Scholar
  36. 36.
    Strangfeld A, Gäwert L, Bussmann A et al (2009) Therapie mit Biologika bei älteren Patienten mit rheumatoider Arthritis – Ergebnisse aus dem deutschen Biologika-Register RABBIT. Akt Rheumatol 34:291–298CrossRefGoogle Scholar
  37. 37.
    Tutuncu Z, Reed G, Kremer J, Kavanaugh A (2006) Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 65:1226–1229PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Wehling M, Burkhardt H (2011) Arzneitherapie für Ältere. Springer Verlag Heidelberg, Berlin, New YorkGoogle Scholar
  39. 39.
    Westhoff G, Weber C, Zink A (2006) Komorbidität bei früher rheumatoider Arthritis. Z Rheumatol 65:487–496PubMedCrossRefGoogle Scholar
  40. 40.
    Wiesner G, Grimm J, Bittner E (2003) Multimorbidität in Deutschland. Stand – Entwicklung – Folgen. Robert-Koch-Institut, Berlin, S 3–194Google Scholar
  41. 41.
    Witham MD (2011) Drug trials and older people – time to embrace the complexity of age. Drugs Aging 28:679–680PubMedCrossRefGoogle Scholar
  42. 42.
    Zulman DM, Sussman JB, Chen X et al (2011) Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 7:783–790CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Rheumatologisches PraxiszentrumMünchenDeutschland
  2. 2.Deutsches Rheuma-Forschungszentrum (DRFZ)BerlinDeutschland
  3. 3.Klinik für Innere Medizin II, Rheumatologie/Immunologie, RheumazentrumKlinikum Südstadt RostockRostockDeutschland

Personalised recommendations